Publications by authors named "D Califano"
Background: Ovarian cancer (OvC) constitutes significant management challenges primarily due to its late-stage diagnosis and the development of resistance to chemotherapy. The standard treatment regimen typically includes carboplatin and paclitaxel, with the addition of poly (ADP-ribose) polymerase inhibitors for patients with high-grade serous ovarian cancer (HGSOC) harboring BRCA1/2 mutations. However, the variability in treatment responses suggests the need to investigate factors beyond BRCA1/2 mutations, such as DNA repair mechanisms and epigenetic alterations.
View Article and Find Full Text PDFThe axis CXCL12-CXCR4 is highly expressed in ovarian cancer where contributes to disease progression. Aim of the work was to evaluate the effect of the newly developed CXCR4 antagonist R54 on human ovarian cancer cells aggressiveness. CXCL12-CXCR4 axis was evaluated in human ovarian cancer cells through proliferation, migration and signaling CXCL12-dependents.
View Article and Find Full Text PDFArticle Synopsis
- In ovarian cancer, a comprehensive study examined various metabolism-related markers to understand their prognostic value, but results showed mixed outcomes in large patient groups.
- The study used advanced techniques on tissue samples from over 300 patients to analyze markers tied to glycolysis, glutamine metabolism, and hypoxia, but found that only one marker (GLS) hinted at a connection to patient survival, which was not statistically significant after adjustments.
- Ultimately, the research highlights the diversity of metabolism markers in ovarian cancer and suggests their expression patterns may still be relevant for future drug development, even if they don't currently correlate with treatment outcomes.
Article Synopsis
- There are currently no specific biomarkers to identify patients with advanced ovarian carcinoma who are responsive to bevacizumab (BEV), a key treatment option.
- A study analyzed TP53 mutations and p53 expression in advanced ovarian cancer patients undergoing BEV treatment, finding that unclassified missense TP53 mutations significantly improved overall survival.
- The results suggest that unclassified TP53 mutations could serve as a favorable prognostic indicator in these patients, indicating the need for further research to explore their potential role in predicting treatment outcomes.
Article Synopsis
- The study aims to determine factors that predict sensitivity to nivolumab in patients with metastatic renal cell carcinoma (mRCC) by analyzing immune cell profiles, specifically peripheral blood NK cells and regulatory T-cells (Tregs).
- A total of 57 mRCC patients and 62 healthy donors were analyzed for various immune cell characteristics over the first year of treatment, using statistical methods to identify key predictors.
- Results indicated that KIR2DL2/DL3+ NK cells and Helios+ Tregs at pretreatment serve as important predictors of nivolumab response, with specific thresholds related to overall survival (OS) and progression-free survival (PFS) showing their potential significance in treatment outcomes.